FRIDAY, Oct. 1, 2021 (HealthDay News) — Intranasal corticosteroid (INCS) therapy is associated with a lower risk for COVID-19-related hospitalization, intensive care unit (ICU) admission, and death, according to a study recently published in the Journal of Allergy and Clinical Immunology: In Practice.

Ronald Strauss, M.D., from the Cleveland Allergy and Asthma Center, and colleagues used data from the Cleveland Clinic COVID-19 Research Registry to find propensity-matched individuals positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection treated with and without INCS before SARS-CoV-2 infection (April 1, 2020, to March 31, 2021).

The researchers found that compared with nonusers, INCS users had a lower risk for hospitalization (adjusted odds ratio, 0.78), ICU admission (adjusted odds ratio, 0.77), and in-hospital mortality (adjusted odds ratio, 0.76). Even after adjusting for baseline blood eosinophil count (measured before SARS-CoV-2 testing) in a subset of 30,289 individuals, the beneficial effect of INCS was significant. “This study shows the importance of the nose in COVID-19 infection,” a coauthor said in a statement. “The nose, in this instance is the gateway to our bodies, allowing the virus to enter and replicate within. The use of intranasal corticosteroids may help disrupt that gateway.”

For latest news and updates

Abstract/Full Text

Copyright © 2021 HealthDay. All rights reserved.
healthday